300482.SZ
万孚生物
SZSE · Healthcare · C 制造业 · CN
CNY 16.00
−8.05%Aug 23, 2026, 08:14 UTC
Wondfo Biotech received 7 chemiluminescence medical device registration certificates from the Guangdong Provincial Drug Administration, covering test kits for homocysteine, insulin, glycated hemoglobin controls and calibrators, laminin, procollagen III N-terminal peptide, and collagen IV, for liver disease, diabetes, and cardiovascular disease testing.
Source:Aug 23, 2026, 07:34 UTC
Wondfo Biotech announced its first-half 2026 results: revenue of 1.039 billion yuan, down 16.63% year-on-year; net profit attributable to shareholders of 123 million yuan, down 35.24% year-on-year.
Source:Aug 6, 2026, 11:13 UTC
Wondfo Biotech's controlling shareholder Wang Jihua increased his shareholding in the company by 1.156 million shares from August 4 to 6, 2026, with a cumulative increase amount of 20.0441 million yuan; after the increase, his shareholding ratio rose to 10.84%, and the combined ratio with his concerted action parties rose to 31.74%.
Source:Jul 28, 2026, 08:24 UTC
Wondfo Biotech's chairman Wang Jihua plans to increase his stake by 20-40 million yuan between July 29 and October 28, 2026.
Jul 28, 2026, 08:24 UTC
Wondfo Biotech announced a share buyback of 30-60 million yuan at a price not exceeding 27.06 yuan per share, to be completed within 3 months.
Source:Jul 10, 2026, 16:00 UTC
Guangzhou Wondfo Biotech Co., Ltd. donated Wondfo Finecare analyzers and ferritin testing capabilities to the province of Cagayan as the first milestone of the new health initiative.
Source: